Skip to main content

Ye Weiguo's Form 4 filing

Gyre Therapeutics, Inc. (GYRE) · filed May 20, 2026

Accession no.
0001140361-26-022235
Filed
May 20, 2026
Trade date
May 18-19, 2026
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $59.4K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Ye WeiguoCIK 0001985496Officer (Chief Operating Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 18, 2026Common StockMOption exerciseAcquired+200$0.75+$150700,200Direct
May 18, 2026Common StockSSaleDisposed−200$6.62F1−$1,324700,000Direct
May 19, 2026Common StockMOption exerciseAcquired+9,120$0.75+$6,840709,120Direct
May 19, 2026Common StockSSaleDisposed−9,120$6.37F2−$58,094.4700,000Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
May 18, 2026Common StockMOption exerciseDisposed−200$0.00$0936,235Direct
May 19, 2026Common StockMOption exerciseDisposed−9,120$0.00$0927,115Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.6102 to $6.6215. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

F2

The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $6.3002 to $6.4119. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)